X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with SUVEN LIFE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs SUVEN LIFE - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA SUVEN LIFE DISHMAN PHARMA/
SUVEN LIFE
 
P/E (TTM) x 25.1 20.1 125.1% View Chart
P/BV x 3.3 3.7 90.0% View Chart
Dividend Yield % 0.7 1.0 66.0%  

Financials

 DISHMAN PHARMA   SUVEN LIFE
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
SUVEN LIFE
Mar-16
DISHMAN PHARMA/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs374339 110.6%   
Low Rs129144 89.3%   
Sales per share (Unadj.) Rs197.839.2 504.0%  
Earnings per share (Unadj.) Rs21.27.5 284.2%  
Cash flow per share (Unadj.) Rs34.78.8 395.7%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.80.8 95.9%  
Book value per share (Unadj.) Rs179.949.0 367.1%  
Shares outstanding (eoy) m80.69127.28 63.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.36.2 20.7%   
Avg P/E ratio x11.932.4 36.7%  
P/CF ratio (eoy) x7.227.5 26.3%  
Price / Book Value ratio x1.44.9 28.4%  
Dividend payout %9.426.8 35.2%   
Avg Mkt Cap Rs m20,30630,732 66.1%   
No. of employees `0000.81.0 86.9%   
Total wages/salary Rs m5,355416 1,286.0%   
Avg. sales/employee Rs Th19,252.75,236.1 367.7%   
Avg. wages/employee Rs Th6,459.5436.5 1,479.9%   
Avg. net profit/employee Rs Th2,064.1995.5 207.3%   
INCOME DATA
Net Sales Rs m15,9614,995 319.5%  
Other income Rs m265194 137.2%   
Total revenues Rs m16,2265,189 312.7%   
Gross profit Rs m4,1031,233 332.9%  
Depreciation Rs m1,091167 652.3%   
Interest Rs m94454 1,742.4%   
Profit before tax Rs m2,3341,205 193.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624255 244.5%   
Profit after tax Rs m1,711950 180.2%  
Gross profit margin %25.724.7 104.2%  
Effective tax rate %26.721.2 126.2%   
Net profit margin %10.719.0 56.4%  
BALANCE SHEET DATA
Current assets Rs m11,0184,986 221.0%   
Current liabilities Rs m9,5171,042 913.1%   
Net working cap to sales %9.479.0 11.9%  
Current ratio x1.24.8 24.2%  
Inventory Days Days11061 181.2%  
Debtors Days Days3539 89.0%  
Net fixed assets Rs m16,3043,126 521.6%   
Share capital Rs m161127 126.8%   
"Free" reserves Rs m12,9073,717 347.2%   
Net worth Rs m14,5166,236 232.8%   
Long term debt Rs m4,189432 969.1%   
Total assets Rs m29,8058,079 368.9%  
Interest coverage x3.523.2 14.9%   
Debt to equity ratio x0.30.1 416.4%  
Sales to assets ratio x0.50.6 86.6%   
Return on assets %8.912.4 71.7%  
Return on equity %11.815.2 77.4%  
Return on capital %17.518.9 92.9%  
Exports to sales %24.887.5 28.3%   
Imports to sales %3.712.2 30.6%   
Exports (fob) Rs m3,9564,371 90.5%   
Imports (cif) Rs m596611 97.6%   
Fx inflow Rs m4,9524,666 106.1%   
Fx outflow Rs m697942 74.0%   
Net fx Rs m4,2553,724 114.2%   
CASH FLOW
From Operations Rs m2,786922 302.2%  
From Investments Rs m-1,529-619 246.9%  
From Financial Activity Rs m-941-698 134.8%  
Net Cashflow Rs m316-396 -80.0%  

Share Holding

Indian Promoters % 61.4 63.4 96.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 0.0 -  
FIIs % 12.7 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 36.5 60.5%  
Shareholders   46,261 37,287 124.1%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   WOCKHARDT LTD.  J.B.CHEMICALS  MERCK LTD  ASTRAZENECA PHARMA  FRESENIUS KABI ONCO.  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS